

better for individual scientists to sit back, relax, and wonder if an isolated bit of research is worthy of individual attention. I can appreciate the necessity of establishing oneself in a particular field, but I have never thought that generating long lists of little experiments is the way to do it.

W. A. VAN SICKLE
*Department of Pharmacology,
 Boston University School of Medicine,
 Boston, Massachusetts 02118*

Funding R & D

Thelma Carter, in her letter "Investing in science" (12 Nov., p. 638), raises interesting and important points concerning the funding of research and development projects through tax-sheltered investment opportunities. I should like to make some comments, particularly with respect to the growing use of research and development limited partnership (RDLP's).

The private sector has been successful in financing R & D arrangements by taking advantage of the appropriate tax laws. An estimated 3 percent of total tax shelter volume during 1981 involved RDLP arrangements (1), and evidence from trade and industry publications indicates that the percentage is increasing. The RDLP is a mechanism available to both individual entrepreneurs and corporate entities in funding R & D efforts. The RDLP is an effective alternative to traditional sources of R & D funding, such as retained earnings, stock sale, or borrowed money. No repayment is necessary if the RDLP is unsuccessful. The funds are supplied by limited partners who are usually investors in high tax brackets. These investors anticipate a tax reduction in the first year based on the ability to reduce taxable income from other sources by an amount equal to a substantial portion of their investment in the partnership. The investors also anticipate a substantial return on investment if the new technology is licensed or sold upon completion of the R & D project. If the partnership is properly arranged, the investor's income may be taxable at capital gains rates. These rates for individuals were reduced from 28 percent to a maximum of 20 percent by the Economic Recovery Tax Act of 1981.

Carter's suggested use of professional societies as clearinghouses to maintain registers of projects and patents available for implementation is an idea worthy of further exploration. Clearly, a source of basic information is needed

concerning novel mechanisms for financing commercial R & D activities.

The formation of RDLP's involves complex legal and business considerations, and the guidance of experienced and reputable advisers is vital.

To assist the private sector in developing an understanding of RDLP's, the Department of Commerce recently prepared a document entitled "Information and steps to form research and development limited partnerships." Copies may be obtained for \$10 by ordering document number PB 83-131516 from the Sales Department of the National Technical Information Service, 5285 Port Royal Road, Springfield, Virginia 22161.

EGILS MILBERGS
*Office of Productivity, Technology,
 and Innovation, Department of
 Commerce, Washington, D.C. 20230*

References

1. P. A. Dreyfus, *Money*, August 1981, p. 87.

Interferon Research

Barbara J. Culliton, in her article regarding the settlement of the interferon affair by researchers, the University of California, and Hoffmann-La Roche (News and Comment, 28 Jan., p. 372), does not discuss one essential feature. The initial research was paid for by taxpayers, through the National Institutes of Health (NIH); and it was this research that was elaborated on by the drug company scientists in their attempt to generate large amounts of interferon. The question then is, Who gets the financial reward if the protein proves to be of commercial value? As it now stands resolved both the University of California and Hoffmann-La Roche will get something; but what about the taxpayer? Without the initial funding by NIH, for the establishment of the cell line, Hoffmann-La Roche might have gotten nowhere. Yet, in the final conclusion, any monies generated by the possible commercial success of interferon will not flow back to NIH (that is, the taxpayer). Thus, we simple taxpayers are paying twice; once for the research funded by our monies, and second for the opportunity to buy a product that was generated by this initial research. My suggestion is that the price of commercially available interferon should be the cost of making it by Hoffmann-La Roche, plus a profit, plus the cost of the development by Hoffmann-La Roche, but minus the cost of the research done through NIH funding. Alternatively, let Hoffmann-La

Roche set any price it wishes, but a certain percentage should go back to NIH, either to be put back into the general governmental kitty or into specific research funds.

PHILIP SIEKEVITZ
*Rockefeller University,
 1230 York Avenue, New York 10021*

Culliton's article concerning the settlement of the lawsuit between Hoffmann-La Roche and the University of California contains two statements relevant to the scientific chronology of events that should be clarified.

The statement, "Gallo . . . observed that KG-1 produced modest quantities of interferon" implies that this information was imparted to me before or at the time we received the KG-1 cells. In screening media from a large number of cells growing in his laboratory, we found several that contained interferon (1) and requested those corresponding cell lines, which Gallo generously sent to me without restrictions of any sort. The KG-1 cells were among them. We did not know about Gallo's observations until long after we received the cells and developed them into good interferon producers.

After developing conditions for good interferon production with these cells, we isolated messenger RNA from them so that we could clone the "interferon gene." The construction and identification of the first recombinant human leukocyte interferon A clone was accomplished in my laboratory (2), not at Genentech. It contained most, but not all, of the coding sequence for leukocyte interferon A. This clone was brought to Genentech by scientists from my laboratory and used to screen their library of clones prepared from messenger RNA we supplied. With this initial clone, my colleagues at Genentech, under contract to Roche, subsequently isolated a full-length clone of leukocyte interferon A and others and efficiently constructed an expression vector for a mature leukocyte interferon for the first time (3).

SIDNEY PESTKA
*Roche Institute of Molecular Biology,
 Nutley, New Jersey 07110*

References

1. P. C. Familletti and S. Pestka, *Antimicrob. Agents Chemother.* **20**, 1 (1981).
2. S. Maeda et al., *Proc. Natl. Acad. Sci. U.S.A.* **77**, 7010 (1980); *ibid.* **78**, 4648 (1981).
3. D. V. Goeddel, *Nature (London)* **287**, 411 (1980).

Erratum: Two taxonomic errors appeared in the report "Oak leaf quality declines in response to defoliation by gypsy moth larvae" by J. C. Schultz and I. T. Baldwin (9 July 1982, p. 149). In the first column on page 149, *Quercus rubrum* should have been *Quercus rubra* L., and in the first column on page 150, *Q. nigra* should have been *Q. velutina* Lam.